Current Report Filing (8-k)
06 November 2020 - 8:29AM
Edgar (US Regulatory)
0001035354
false
0001035354
2020-11-05
2020-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): November 5,
2020
Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
|
Delaware
|
|
001-31326
|
|
84-1368850
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
950 Winter Street
Waltham, MA
|
|
02451
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number,
including area code): (781) 577-5300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.01 par value per share
|
ELOX
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 5, 2020, Eloxx Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2020 and providing a business
update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
The information in this Current Report on Form 8-K, including
the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities
of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities
Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation
language in such filing, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ELOXX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Neil S. Belloff
|
|
|
Name:
|
Neil S. Belloff
|
|
|
Title:
|
Chief Operating Officer
and General Counsel
|
Date: November 5, 2020
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Nov 2023 to Nov 2024
